Literature DB >> 1625214

Effects of pH upon the inhibition by sulphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle.

I Findlay1.   

Abstract

The effect of pH was tested upon the inhibition of ATP-sensitive K+ (KATP) channels caused by the sulphonylurea drugs tolbutamide and glibenclamide. KATP channels and currents (I-KATP) were activated with SR 44866 in ventricular myocytes isolated from guinea pig hearts. Modification of either external or internal pH had little effect upon the background K+ current (IK1). External pH had no consistent effects upon I-KATP. The application of NH4Cl inhibited I-KATP and its withdrawal caused a slight rebound activation. Compared with the results obtained at pHo 7.4, inhibition of I-KATP by the sulphonylurea drugs was enhanced at pHo 6.5 and reduced at pHo 8.4. The kinetics of the recovery of I-KATP was independent of pHo. Neither internal pH 6.5 nor NH4Cl had any effect upon sulphonylurea-induced inhibition of I-KATP. The dose-response curves for inhibition of I-KATP at different pHo's were found to coincide when plotted for the unionized concentrations of the drugs. It is concluded that it is the unionized forms of the sulphonylurea drugs which are responsible for closure of KATP channels in cardiac muscle. In consequence, extracellular acidification during ischemia will increase the effective concentration of glibenclamide and may be responsible for the cardiovascular disorders associated with this treatment in noninsulin-dependent diabetics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1625214

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  ATP-sensitive K+ channels are functional in expiratory neurones of normoxic cats.

Authors:  O Pierrefiche; A M Bischoff; D W Richter
Journal:  J Physiol       Date:  1996-07-15       Impact factor: 5.182

Review 2.  Effects of glibenclamide upon ATP-sensitive K channels during metabolic inhibition of isolated rat cardiac myocytes.

Authors:  I Findlay
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

Review 3.  Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus.

Authors:  S H Wilson; F P Kennedy; K N Garratt
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Attenuation by phentolamine of hypoxia and levcromakalim-induced abbreviation of the cardiac action potential.

Authors:  D Tweedie; G Boachie-Anash; C G Henderson; K A Kane
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

5.  Distinct modes of blockade in cardiac ATP-sensitive K+ channels suggest multiple targets for inhibitory drug molecules.

Authors:  I Benz; M Kohlhardt
Journal:  J Membr Biol       Date:  1994-12       Impact factor: 1.843

6.  Drugs acting on SUR1 to treat CNS ischemia and trauma.

Authors:  J Marc Simard; S Kyoon Woo; Sergei Bhatta; Volodymyr Gerzanich
Journal:  Curr Opin Pharmacol       Date:  2007-11-26       Impact factor: 5.547

7.  Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.

Authors:  J Marc Simard; Mingkui Chen; Kirill V Tarasov; Sergei Bhatta; Svetlana Ivanova; Ludmila Melnitchenko; Natalya Tsymbalyuk; G Alexander West; Volodymyr Gerzanich
Journal:  Nat Med       Date:  2006-03-19       Impact factor: 53.440

8.  Antagonism by lipophilic quaternary ions of the K+ channel opener, levcromakalim, in vascular smooth muscle.

Authors:  G A McPherson; A E Piekarska
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

9.  Stilbene disulfonates block ATP-sensitive K+ channels in guinea pig ventricular myocytes.

Authors:  T Furukawa; L Virág; T Sawanobori; M Hiraoka
Journal:  J Membr Biol       Date:  1993-12       Impact factor: 1.843

Review 10.  Glibenclamide in cerebral ischemia and stroke.

Authors:  J Marc Simard; Kevin N Sheth; W Taylor Kimberly; Barney J Stern; Gregory J del Zoppo; Sven Jacobson; Volodymyr Gerzanich
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.